During the third quarter, Alta Wealth Advisors LLC trimmed its Eli Lilly holdings by 17.0%, selling 522 shares and ending the period with 2,541 shares valued at $1.94 million. This reduction follows a broader trend among institutions: 82.53% of outstanding shares are held by hedge funds and other institutional investors. Notable activity included Sumitomo Mitsui Financial Group acquiring a new stake worth $27,000 in Q2, and Steph & Co. boosting its position by 290%, bringing its total to 39 shares valued at $30,000.

Eli Lilly reported third-quarter revenue of $17.60 billion, up 53.9% year-over-year and exceeding analyst forecasts by $1.51 billion. Adjusted EPS came in at $7.02, beating estimates by $0.60 and driving a net margin of 30.99% and return on equity of 109.52%. The company reiterated full-year 2025 EPS guidance in the range of $23.00 to $23.70, aligning with consensus expectations of $23.48.

The board approved a quarterly dividend of $1.73 per share, payable March 10 to holders of record on February 13, representing a 15% increase from the prior payout and an annualized yield of 0.7%. Eli Lilly’s balance sheet remains robust, with a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55, supporting ongoing R&D investments and shareholder distributions.

Eli Lilly is accelerating its digital transformation with multiple AI partnerships. In September, it launched TuneLab, an AI drug-discovery platform offered free to smaller biotech firms in exchange for data-sharing. It followed with a collaboration with Nvidia to build the sector’s most powerful AI supercomputer, and is establishing a joint AI lab in the San Francisco Bay Area. These initiatives aim to shorten development timelines and reduce research costs for next-generation therapies.